Levi N Kanu

Dr. Levi N Kanu

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2017 in Progress in Retinal and Eye Research
Verified
Journal Article
Closed access
IDIan D. Danford
Ian D. Danford
LVLana D. Verkuil
Lana D. Verkuil
DCDaniel J. Choi
Daniel J. Choi
DCDavid W. Collins
David W. Collins
HGHarini V. Gudiseva
Harini V. Gudiseva
JOJoan M. O'BRien
Joan M. O'BRien

1 October 2016 in Experimental Eye Research
Verified
Journal Article
Closed access
DSDelu Song
Delu Song
LKLevi N Kanu
Levi N Kanu
YLYafeng Li
Yafeng Li
KKKristen L. Kelly
Kristen L. Kelly
RBRupak K. Bhuyan
Rupak K. Bhuyan
JDJoshua L. Dunaief
Joshua L. Dunaief

27 February 2021 in Seminars in Ophthalmology
Verified
Journal Article
Closed access
LKLevi N Kanu
Levi N Kanu
JCJoseph B Ciolino
Joseph B Ciolino
Nerve growth factor (NGF), the prototypical neurotrophin first discovered in the 1950s, has recently garnered increased interest as a therapeutic agent promoting neuronal health and regeneration. After gaining orphan drug status within the last decade, NGF-related research and drug development has accelerated. The purpose of this article is to review the preclinical and clinical evidence of NGF in various applications, including central and peripheral nervous system, skin, and ophthalmic disorders. We focus on the ophthalmic applications including not only the FDA-approved indication of neurotrophic keratitis but also retinal disease and glaucoma. NGF represents a promising therapy whose therapeutic profile is evolving. The challenges related to this therapy are reviewed, along with possible solutions and future directions.

7 February 2020 in Translational Vision Science & Technology
Verified
Journal Article
Open access
PDF file
SJSayena Jabbehdari
Sayena Jabbehdari
GYGhasem Yazdanpanah
Ghasem Yazdanpanah
LKLevi N Kanu
Levi N Kanu
KAKhandaker N. Anwar
Khandaker N. Anwar
XSXiang Shen
Xiang Shen
ADAli Djalilian
Ali Djalilian
Purpose: A reproducible protocol for the production of corneal mesenchymal stem/stromal cells (cMSCs) is necessary for potential clinical applications. We aimed to describe successful generation and expansion of cMSCs using an explant method. Methods: Corneoscleral rims of human cadaveric eyes were divided into four pieces and used as explants to allow outgrowth of cMSCs (passage 0, or P0). The cells were subcultured at a 1:10 ratio until passage 5 (P5). The characteristics as well as therapeutic effects of expanded cMSCs were evaluated both in vitro, using a scratch assay, and in vivo using epithelial debridement and chemical injury mouse models. Results: All explants demonstrated outgrowth of cells by 7 days. Although the initial outgrowth included mixed mesenchymal and epithelial cells, by P1 only cMSCs remained. By subculturing each flask at a ratio of 1:10, the potential yield from each cornea was approximately 12 to 16 × 1010 P5 cells. P5 cMSCs demonstrated the cell surface markers of MSCs. The secretome of P5 cMSCs induced faster closure of wounds in an in vitro scratch assay. Subconjunctival injection of P5 cMSCs in mouse models of mechanical corneal epithelial debridement or ethanol injury led to significantly faster wound healing and decreased inflammation, relative to control. Conclusions: cMSCs can be reproducibly derived from human cadaveric corneas using an explant method and expanded with preservation of characteristics and corneal wound healing effects. Translational Relevance: The results of our study showed that cMSCs produced using this scheme can be potentially used for clinical applications.

14 May 2020 in Current Eye Research
Verified
Journal Article
Closed access
SJSayena Jabbehdari
Sayena Jabbehdari
GYGhasem Yasdanpanah
Ghasem Yasdanpanah
LKLevi N Kanu
Levi N Kanu
ECEric Chen
Eric Chen
KKKai Kang
Kai Kang
ADAli Djalilian
Ali Djalilian
Objectives: The conditioned-medium derived from corneal mesenchymal stromal cells (cMSCs) has been shown to have wound healing and immunomodulatory effects in corneal injury models. Here, the therapeutic effects of lyophilized cMSC conditioned-medium were compared with fresh conditioned-medium. Methods: The epithelial wound healing effects of fresh and lyophilized cMSC conditioned-medium were compared with conditioned-medium from non-MSC cells (corneal epithelial cells) using scratch assay. To evaluate the anti-inflammatory effects of fresh and lyophilized cMSC conditioned-media, macrophages were stimulated by a Toll-Like Receptor (TLR) ligand followed by treatment with the conditioned-media and measuring the expression of inflammatory genes. In vivo wound healing effects of fresh and lyophilized cMSC conditioned-media were assessed in a murine model of cornea epithelial injury. Results: Both fresh and lyophilized cMSCs-derived conditioned-medium induced significantly faster closure of in vitro epithelial wounds compared to conditioned-medium from non-MSC cells (P<0.0001). Treating stimulated macrophages with fresh or lyophilized cMSCs-derived conditioned-media significantly decreased the expression of inflammatory genes compared to control (P<0.0001). Murine corneal epithelial wounds were healed by 87.6±2.7% and 86.2±4.6% following treatment with fresh and lyophilized cMSC conditioned-media, respectively, while the control was healed by 64.7±16.8% (P<0.05). Conclusion: Lyophilized cMSC-derived conditioned-medium is as effective as fresh conditioned-medium in promoting wound healing and modulating inflammation. The results of this study support the application of lyophilized cMSCs-derived conditioned-medium, which allows for more extended storage, as a promising non-invasive option in the treatment of corneal wounds.

2 July 2010 in Langmuir
Verified
Journal Article
Closed access
JRJatinder S. Randhawa
Jatinder S. Randhawa
LKLevi N Kanu
Levi N Kanu
GSGursimranbir Singh
Gursimranbir Singh
DGDavid Gracias
David Gracias